275 related articles for article (PubMed ID: 34800168)
1. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
Sriwastava S; Chaudhary D; Srivastava S; Beard K; Bai X; Wen S; Khalid SH; Lisak RP
J Neurol; 2022 Mar; 269(3):1678-1687. PubMed ID: 34800168
[TBL] [Abstract][Full Text] [Related]
2. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
Corsten CEA; Huygens SA; Versteegh MM; Wokke BHA; Smets I; Smolders J
Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
[TBL] [Abstract][Full Text] [Related]
3. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
Sriwastava S; Kataria S; Srivastava S; Kazemlou S; Gao S; Wen S; Saber H; Tripathi R; Sheikh Z; Peterson S; Gwinn R; Bernitsas E
J Neuroimmunol; 2021 Nov; 360():577721. PubMed ID: 34547511
[TBL] [Abstract][Full Text] [Related]
4. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
Roy R; Alotaibi AA; Freedman MS
CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
[TBL] [Abstract][Full Text] [Related]
5. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
Baker D; Forte E; Pryce G; Kang AS; James LK; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2023 Jan; 69():104425. PubMed ID: 36470168
[TBL] [Abstract][Full Text] [Related]
6. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
[TBL] [Abstract][Full Text] [Related]
7. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
Dumitrescu L; Papathanasiou A; Coclitu C; Garjani A; Evangelou N; Constantinescu CS; Popescu BO; Tanasescu R
Expert Opin Pharmacother; 2023 Mar; 24(4):495-509. PubMed ID: 36946625
[TBL] [Abstract][Full Text] [Related]
8. [Progressive Multifocal Leukoencephalopathy: An Overview of Current Topics].
Yukitake M
Brain Nerve; 2022 Oct; 74(10):1179-1187. PubMed ID: 36198643
[TBL] [Abstract][Full Text] [Related]
9. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Oshima Y; Tanimoto T; Yuji K; Tojo A
Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
[TBL] [Abstract][Full Text] [Related]
10. Progressive multifocal leukoencephalopathy after fingolimod treatment.
Berger JR; Cree BA; Greenberg B; Hemmer B; Ward BJ; Dong VM; Merschhemke M
Neurology; 2018 May; 90(20):e1815-e1821. PubMed ID: 29669908
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients.
Sharma K; Chaudhary D; Beard K; Srivastava S; Khalid SH; Sriwastava S
Mult Scler Relat Disord; 2022 Mar; 59():103675. PubMed ID: 35168095
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Chun J; Giovannoni G; Hunter SF
Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing-remitting multiple sclerosis: findings from randomized controlled trials.
Yang S; Li X; Wang J; Wang T; Xu Z; Gao H; Chen G
Neurol Sci; 2022 Jun; 43(6):3565-3581. PubMed ID: 35243548
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
[TBL] [Abstract][Full Text] [Related]
15. Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis.
Volpi C; Orabona C; Macchiarulo A; Bianchi R; Puccetti P; Grohmann U
Expert Opin Drug Discov; 2019 Nov; 14(11):1199-1212. PubMed ID: 31389262
[No Abstract] [Full Text] [Related]
16. Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more.
Constantinescu V; Akgün K; Ziemssen T
Expert Opin Drug Metab Toxicol; 2022 Oct; 18(10):675-693. PubMed ID: 36260948
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
McGinley MP; Cohen JA
Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
[TBL] [Abstract][Full Text] [Related]
18. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
[TBL] [Abstract][Full Text] [Related]
19. Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.
Comi G; Hartung HP; Bakshi R; Williams IM; Wiendl H
Drugs; 2017 Oct; 77(16):1755-1768. PubMed ID: 28905255
[TBL] [Abstract][Full Text] [Related]
20. New disease-modifying therapies and new challenges for MS.
Yadav V; Bourdette D
Curr Neurol Neurosci Rep; 2012 Oct; 12(5):489-91. PubMed ID: 22760478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]